AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

The third and final part of the Phase I/II trial is evaluating avelumab in combination with imneskibart and low-dose, subcutaneous aldesleukin, an IL-2 therapy. Avelumab is described as a human ...